Meeting
2022 ASCO Annual Meeting
A single-institution, retrospective examination of new contrast enhancement, progression, and pseudoprogression in IDH mutant glioma.
Authors
Ethan Wetzel
UCLA, Los Angeles, CA
Ethan Wetzel , Blaine S.C. Eldred , Vicki Liu , Serendipity Zapanta Rinonos , Negar Khanlou , Linda M. Liau , Phioanh Leia Nghiemphu , Timothy Francis Cloughesy , Benjamin M. Ellingson , Albert Lai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2043)
DOI
10.1200/JCO.2022.40.16_suppl.2043
Abstract #
2043
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Population-based retrospective analysis of response assessment criteria in patients with glioblastoma.
First Author: Parandoush Abbasian
Poster
2020 ASCO Virtual Scientific Program
Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424.
First Author: Erica Hlavin Bell
Poster
2016 ASCO Annual Meeting
Overall survival in patients with glioblastoma before and after bevacizumab approval.
First Author: Derek Richard Johnson
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger